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Acute respiratory distress syndrome (ARDS) is a severe
form of lung injury characterized by permeability edema
and lung inflammation. The diagnostic criteria for ARDS
includes the acute onset of severe hypoxemia with diffuse
bilateral opacities on chest radiograph that are not due to
left atrial hypertension; alveolar damage may result from
either direct or indirect lung injury (1). In addition,
pulmonary vascular resistance (PVR) is increased and right
ventricular (RV) function impaired secondary to hypoxic
and mediator induced vasoconstriction, as well as extensive
endothelial damage and structural remodeling of the
pulmonary vasculature (2,3).
Conventional methods for optimizing oxygen delivery in
ARDS include mechanical ventilation and hemodynamic
support. Hypotension and progressive hypoxemia limited
initial attempts to improve ventilation–perfusion matching,
PVR and RV function with systemic vasodilators (4).
Therapy with prostaglandin E1 and a liposomal derivative,
agents with both vasoactive and anti-inflammatory proper-
ties, were also disappointing (5,6). The introduction of
inhaled nitric oxide (iNO?) as a selective pulmonary
vasodilator that reverses hypoxic pulmonary vasoconstric-
tion however, renewed interest in pharmacological treat-
ments aimed at improving ventilation–perfusion matching
and reducing pulmonary hypertension in ARDS (7,8).
Nitric oxide (NO?) is an endogenously formed free
radical gas with numerous biological actions. It regulates
or affects vascular tone, leukocyte–endothelial interactions,
platelet aggregation, neurotransmission and cell-mediated
immune responses through cGMP-dependent and -inde-
pendent mechanisms. NO? rapidly diffuses across lipid
membranes giving it access to intracellular targets, not only
in the cell of origin, but also in nearby cells. In addition,
NO? may form S-nitrosyl compounds and, consequently,
exist in a more stable state. NO? inhalation therapy involves
the addition of NO? gas to the inspiratory circuit during
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0954-6111/00/111023+06 $35?00/0preferentially delivered to well-ventilated lung units and to
readily diffuse across the airway and alveolar epithelium
into pulmonary vascular smooth muscle cells, causing
relaxation through increased cGMP production. Limiting
vasodilation to pulmonary vessels serving well-aerated lung
regions should improve ventilation–perfusion (V/Q) match-
ing. Any NO? gas that diffuses into the circulation should
be quickly bound to hemoglobin and perhaps other
proteins, thus minimizing systemic hemodynamic actions.
Improved V/Q matching should increase the partial
pressure of oxygen in arterial blood allowing for a
reduction in the fraction of inspired oxygen or the intensity
of mechanical ventilation (e.g. level of positive pressure). It
is through this effect on gas exchange that iNO? is usually
hypothesized to improve outcome in ARDS.
In 1993, three articles describing the use of iNO? in
ARDS were published (9–11). iNO? consistently reduced
venous admixture and significantly increased oxygenation.
Its effect on the pulmonary circulation was variable,
depending on the dose used. In 10 patients with severe
ARDS long-term iNO? therapy was provided and survival
was 90% (9,10). These impressive initial results were
followed by numerous short-term, uncontrolled studies
also reporting favorable effects of iNO? on oxygenation and
pulmonary hemodynamics in acute lung injury. Within a
brief period of time, iNO? was frequently used for ARDS
management in many ICUs around the world (12). Recent
randomized, controlled clinical trials rigorously evaluating
the long-term effects of iNO? in ARDS, however, question
the benefit of this therapy (13–16). In this paper we hope to
provide a balanced assessment, based on published
evidence, of the potential benefits and risks associated with
the use of iNO? in adults with ARDS.
Effect of iNO? on oxygenation
Short-term (i.e. hours) exposure to iNO? can improve
oxygenation in adult patients with ARDS. The reported
average increase in PaO2/FiO2 is 25% with delivery of iNO?
over the range of 5–40 parts per million (ppm). Favorable
effects on oxygenation also occur at the parts per billion
(ppb) level (17). If one defines an acute ‘response’ as an
increase in PaO2/FiO2 of at least 10mm Hg or4 20%, then
approximately 60% of patients have an acute improvement
in oxygenation with iNO? (13–16,18–20). The Inhaled# 2000 HARCOURT PUBLISHERS LTD
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II trial, reported that 60% of patients treated with iNO?
had an acute increase in oxygenation; in contrast, only 24%
of ARDS patients treated with placebo had a similar
improvement (13).
The distribution of pulmonary blood flow (PBF) may
influence responsiveness to iNO? (21). In an oleic acid
model of acute lung injury, animals with preserved hypoxic
pulmonary vasoconstriction naturally shunted PBF away
from areas of pulmonary edema to maximize ventilation–
perfusion matching; iNO? had no effect on oxygenation in
this group. Animals treated with oleic acid and endotoxin
lack hypoxic vasoconstriction and do not shunt blood away
from edematous lung regions, thus their oxygenation was
more severely affected. In this group iNO? significantly
improved oxygenation by altering PBF to non-edematous
lung regions. Thus, the distribution of PBF prior to
initiating iNO? may influence its ability to improve
oxygenation (21).
Whether acute improvements in oxygenation with iNO?
predict a longer-term response was evaluated in a single
center randomized, controlled clinical trial in patients with
severe ARDS. It was found that the acute change in PaO2/
FiO2 after 1 h of iNO? did not correlate with the change
observed after 72 h of therapy. In addition, the presence or
absence of an acute response to iNO? did not predict the
ability to reduce the FiO2 over 72 h or the likelihood
of ARDS reversal (14). Three recent, randomized, con-
trolled clinical trials have evaluated the long-term effects of
iNO? on oxygenation. These studies indicate that, com-
pared to placebo, iNO? improves PaO2/FiO2 during the first
24 h following randomization (13-15). After the first dayTABLE 1. Randomized clinical studies evaluating iNO? in patien
Study No. of patients Study design
Dellinger (13) 177 Prospective, multi-center,
randomized, double-blind,
placebo-controlled clinical
trial
Su
O
m
Michael (14) 40 Prospective, single-center,
randomized, controlled
clinical trial
O
(P
Troncy (15) 30 Prospective, single-center,
randomized, controlled
clinical trial
O
(P
D
Su
Lundin (16) 180 Prospective, multi-center,
randomized, parallel group
clinical trial of patients with
an acute response to iNO?
R
in
T
Pr
fa
M
*Severe respiratory failure defined as either: (i) FiO2 > 0.9 and
10 cm H2O and mean airway pressure at least 20 cmH2O or (ii
apart.following randomization, the changes in oxygenation were
equivalent in the placebo and iNO? groups (Table 1).
In summary, iNO? improves oxygenation acutely in a
majority of patients with ARDS. This acute response
does not predict the longer-term response to this therapy;
in addition, it does not correlate with reversal of ARDS.
Thus, studies focusing on short-term effects of iNO? are
of limited clinical significance. Finally, in patients with
ARDS, iNO? does not lead to a sustained improvement in
oxygenation compared with conventional therapy.
Effect of iNO? on pulmonary artery
pressure
Short-term studies in patients with ARDS report a variable
effect of iNO? on pulmonary artery pressure (9,22–24).
Changes in pulmonary artery pressure can occur with or
without accompanying changes in oxygenation (22,25). The
site of action of iNO? on the pulmonary vasculature is
uncertain, with data supporting effects on both the arterial
and venous circulations (26–28). In patients responding to
iNO? with a decrease in pulmonary artery pressure and
PVR, there can be an associated increase in RV ejection
fraction and lower RV end-systolic and end-diastolic
volumes (25,29). The improvement in RV function is not
associated with a change in cardiac index, suggesting that
the reduction in RV function in these ARDS patients is not
limiting left ventricular systolic function.
In the Inhaled Nitric Oxide in ARDS Study Group’s
trial, 119 (67%) of the 177 patients had a pulmonary arteryts with ARDS
Endpoints Outcome
rvival
xygenation index (FiO2 6
ean airway pressure)/PaO2
No difference between groups
Improved with iNO? days 1–3,
no difference afterwards
xygenation response
aO2/FiO2)
Improved with iNO? up to
24 h, no difference between
groups afterwards
xygenation response
aO2/FiO2)
uration of ventilation
rvival
Improved with iNO? up to 24 h,
no difference between groups
afterwards
No difference between groups
No difference between groups
eversal of acute lung
jury (ALI)
ime to reversal of ALI
event severe respiratory
ilure*
ortality
No difference between groups
No difference between groups
Fewer patients went on to
develop SRF in the iNO? group
No difference between groups
PaO2 5 60mmHg in 3 ABGs 4 h apart with PEEP at least
) FiO2 0.9 with PaO2 5 45mmHg on 2 ABGs at least 2 h
INHALED NITRIC OXIDE IN ADULTS WITH ARDS 1025catheter. In the placebo group there was no acute change in
pulmonary artery pressure, whereas it was reduced by an
average of 2mmHg in the iNO? cohort (13). Inhaled NO?
significantly reduced mean pulmonary artery pressure by
2mmHg compared to the placebo group only at day 1 of
therapy. There was no difference in pulmonary artery
pressure between the groups from days 2–7 (13).
In summary, iNO? has a variable affect on pulmonary
hemodynamics in patients with ARDS. In responsive patients
the reduction in pulmonary artery pressures may be
accompanied by improved RV function. In a controlled trial,
the effect of iNO? vs. placebo was modest and short acting.
Other potential benefits of iNO?
Besides effects on oxygenation and pulmonary hemody-
namics, iNO? may provide other theoretical benefits.
Experimental studies point to several anti-inflammatory
properties of nitric oxide. iNO? prevents the increase in
pulmonary capillary leak caused by oxygen radicals (30,31).
Additionally, supplying exogenous NO? can reduce hydro-
gen peroxide-mediated oxidant injury to cultured pulmon-
ary endothelial cells (32). iNO? also reduces platelet
aggregation (without increasing the bleeding time) and
decreases pulmonary platelet and neutrophil sequestration
(33,34). Inhaling NO? for 4 days at 18 ppm reduces basal,
but not stimulated, hydrogen peroxide production and
CD11b/CD18 adhesion molecule expression by neutrophils
obtained at bronchoalveolar lavage (BAL) from ARDS
patients. Patients treated with iNO? also have decreased
BAL levels of interleukin-6 and interleukin-8 compared to
patients receiving conventional therapy (35).
NO? can produce mild bronchodilation and reverse
methacholine-induced bronchoconstriction (36,37);
whether it has any favorable airway effects in ARDS is
unknown. Finally, in ARDS patients, short-term iNO? at
40 ppm decreases pulmonary transvascular albumin flux
presumably by reducing pulmonary capillary pressure (38).
Although it is unknown whether these experimental and
mostly short-term effects produce long-term clinical benefits,
the controlled clinical trials with iNO? are not encouraging.
Effect of iNO? on clinical endpoints
The Inhaled Nitric Oxide in ARDS Study Group’s phase II
trial enrolled 177 patients from 30 sites within the United
States with ARDS (13). The trial entered patients within
72 h of meeting defined criteria for ARDS (PaO2/
FiO2 200mmHg, bilateral infiltrates on chest radiograph,
and pulmonary capillary wedge pressure 18mmHg or no
clinical evidence of left atrial hypertension). The study
excluded patients with persistent hypotension, vasopressor
use, head injury, multiple organ dysfunction syndrome,
pregnancy, immunocompromized states or a non-pulmon-
ary infection source as a cause of ARDS. With this design
the investigators hoped to maximize the chance for iNO? to
show benefit by excluding patients who had, or were likely
to develop, conditions in which death and duration ofmechanical ventilation were unlikely to be altered by an
improvement in lung function. Patients were randomized to
placebo or 1?25, 5, 20, 40, or 80 ppm iNO?. The primary
clinical outcome assessed was duration of mechanical
ventilation, using the number of days patients were both
alive and off mechanical ventilation during the 28 days after
randomization.
There was no difference between the control group and
pooled iNO? groups in mortality, number of days alive after
reaching oxygenation criteria for extubation, and number
of days alive and off mechanical ventilation during the 28
days following randomization. Patients treated with iNO?
had a greater decrease in their oxygenation index (i.e.
[FiO26mean airway pressure]/PaO2) compared with the
placebo group on days 1–3 after randomization, however,
the individual components of the index were not signifi-
cantly different between the groups after day one. Even the
statistically significant difference on day 1, FiO2 of 0?71 in
the placebo group vs. 0?69 in the iNO? group, is of
questionable clinical importance (Table 1) (13).
The European Study Group of Inhaled Nitric Oxide
conducted a prospective, open, randomized, multi-center
phase III trial of iNO? for acute lung injury (ALI) in 43
hospitals in 11 countries (16). The trial entered patients
within 96 h of intubation and mechanical ventilation for
acute lung injury (unilateral or bilateral infiltrates on chest
radiograph, PaO2/FiO2 165mmHg, PEEP 5 cmH2O,
and mean airway pressure 4 10 cmH2O). The study
excluded patients on mechanical ventilation for 4 96 h at
FiO2 0?5 or mechanical ventilation for more than 10 days,
independent lung ventilation, high dose intravenous vaso-
dilators, severe respiratory failure (FiO2 4 0?9 with PaO2
5 60mmHg on pressure control ventilation with a
respiratory rate of 5–30, PEEP 10 cmH2O, and mean
airway pressure 20 cmH2O or an FiO2 0?9 with a PaO2
5 45mm Hg on two consecutive blood gases 2 h apart),
treatment with extracorporeal lung assist, cardiac failure
(pulmonary capillary wedge pressure 4 18mmHg or LV
ejection fraction 5 50%), intracranial hemorrhage, on-
going treatment for malignancy, AIDS, severe chronic
renal, liver, or pulmonary disease, age 5 18 years,
pregnancy or an underlying disease likely to be fatal. This
study randomized 180 patients who acutely responded to
iNO? (defined as an increase in the PaO2 of 20–25%) to
receive continued iNO? (1–40 ppm) or conventional therapy
alone. The primary endpoint of the study was reversal of
ALI (extubated and receiving5 5 lmin71 of supplemental
oxygen via nasal catheter with a persistent PaO2 4 75 or
83mmHg depending on age or ongoing invasive or non-
invasive ventilation with PEEP 5 cmH2O with a PaO2/
FiO2 4 195–233mmHg depending upon age); the second-
ary endpoints were: (i) frequency of development of severe
respiratory failure, (ii) time to achieve reversal of ALI, (iii)
mortality and hospitalization status at 30 and 90 days and
(iv) safety issues.
There was no difference in reversal of ALI between the
conventional therapy and iNO? treatment groups (54% vs.
61%, respectively). There was no significant difference in
time to reversal of ALI between groups though there was a
slight increase in the development of severe respiratory
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was no difference in mortality between the two patient
cohorts (conventional therapy 40% vs. iNO? therapy 44%).
Post hoc analysis, however, revealed that a higher
percentage of patients in the conventional therapy group
were alive and off mechanical ventilation over time
(P50?01); the mortality at 90 days for conventional
therapy and iNO? were 43?7% and 51?6%, respectively.
In addition, there was a higher incidence of need for
renal replacement therapy in the iNO? treatment group
(Table 1) (16).
In a single-center randomized controlled clinical trial of
patients with ARDS, iNO? improved oxygenation and
reduced pulmonary artery pressure over the first 24 h
compared with placebo. These findings did not persist
beyond the first day. In addition, 30-day mortality and
duration of mechanical ventilation were similar between
groups (Table 1) (15).
Thus, despite a plethora of data showing short-term
favorable effects of iNO? on oxygenation and pulmonary
hypertension in patients with ARDS, randomized con-
trolled clinical studies find that the comparative advantage
in oxygenation and pulmonary artery pressure lasts only
24 h and that iNO? has no benefit on survival or the
duration of mechanical ventilation. Clearly, a transient
improvement in PaO2/FiO2, a secondary endpoint, is an
inadequate surrogate for an improvement in survival, the
primary endpoint.
iNO? in combination therapy
Almost from the outset, iNO? has been routinely used as
part of a multi-layered approach to acute lung injury (12).
iNO? has been advocated as complementary to permissive
hypercapnia, as it partially reverses pulmonary hyperten-
sion induced by hypercapnic acidosis (39). iNO? has also
been used in combination with the prone position to
improve oxygenation in ARDS (40). The greatest interest
has been in combining iNO? with a vasoconstricting agent
that enhances hypoxic vasoconstriction. The goal of
this therapy is to blend two drugs, which can individually
improve oxygenation by different mechanisms, while
still lowering pulmonary artery pressure. While various
reports have presented favorable short-term data, this
approach has not yet been tested in a controlled clinical
trial (41–44).
Adverse effects of iNO?
Reports of inadvertent poisoning with nitrogen oxides
during anesthesia raise the possibility that iNO? could have
a direct toxic effect on the lung and worsen ARDS. At
doses used in most clinical studies (up to 40 ppm) there is
little evidence for a toxic effect of iNO?. NO? also reacts
with hemoglobin to form methemoglobin. At therapeutic
doses, however, this is rarely of concern in adults. In two of
the controlled clinical trials no ARDS patient on iNO?
therapy developed elevated methemoglobin levels (14,15).In the Inhaled Nitric Oxide in ARDS Study Group trial,
2% of patients had methemoglobin concentrations greater
than 5%, but none had levels above 7% (13). Similarly, in
the European Study Group of Inhaled Nitric Oxide trial
only one patient in the iNO? group had a methemoglobin
level greater than 5% (16). Thus, it is prudent to follow
methemoglobin levels during iNO? therapy, however, at
NO? levels 5 40 ppm, methemoglobin levels rarely rise to
clinically significant levels. The spontaneous formation of
nitrogen dioxide (NO2), from the reaction of NO? and
oxygen can cause lung injury. In the United States the
Occupational Safety and Health Administration suggests a
maximum inhaled NO2 level of 5 ppm and recommends
that levels not exceed 1 ppm. In the United Kingdom the
standard set by the Health and Safety Executive is 3 ppm
(45). In the two single-center clinical trials, NO2 levels never
exceeded 1 ppm (14,15). In a multi-center study, three
patients had NO2 levels between 3 and 4 ppm; these patients
were all receiving 80 ppm iNO?. For patients receiving iNO?
concentrations between 1?25 and 40 ppm, mean NO2
concentrations were below 0?5 ppm (13).
Although ARDS patients treated with or without iNO?
have similar levels of PaO2/FiO2 after 24 h of therapy,
stopping iNO? acutely decreases PaO2 and increases
pulmonary artery pressure. While this response may be
severe in only a minority of patients, these effects can be
life-threatening and require reinstitution of iNO? therapy
(19,46,47). This suggests that chronic iNO? therapy inhibits
endogenous production of vasodilators or stimulates the
release of vascoconstrictors. Stopping iNO? then unmasks
these phenomena and can potentially create a crisis.
Inhalation of NO? in patients with reduced left ventri-
cular (LV) systolic function can exacerbate heart failure. In
these patients, iNO? tends to increase the pulmonary
capillary wedge pressure (PCWP). This appears to be due
to a reduction in PVR, which increases pulmonary venous
return to the LV leading to increased LV filling pressures.
These studies have not found a direct inhibitory effect of
iNO? on contractile function (48–50). In one study, iNO?
increased mean PCWP by 23%, with larger increases seen
in the patients with the most severely reduced LV systolic
function (49). iNO? should thus be used with caution in
patients with a history of LV failure.
It was noted previously that iNO? may exert a favorable
anti-inflammatory effect by interacting with certain oxi-
dants (32,35). In a study involving newborns and infants,
however, iNO? decreased superoxide anion production by
polymorphonuclear leukocytes in response to an E. coli
suspension and n-formyl-methionyl-leucyl-phenylalanine
(51). This could have unwanted effects on host defense
and impede the ability to respond to infections. In addition,
iNO? can potentially enhance oxidant injury through the
generation of toxic compounds, such as peroxynitrite.
Finally, the European Study Group’s iNO? trial reported
an increase in the need for renal replacement therapy in
patients randomized to iNO? compared with conventional
therapy (16). Other randomized clinical trials have not
reported similar findings (13,14). Thus, the significance of
this observation is uncertain but suggests that renal
function should be closely monitored.
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In summary, iNO? acutely increases PaO2/FiO2 and slightly
reduces pulmonary artery pressure in patients with ARDS.
When these effects are compared to a control group, the
benefits last approximately 24 h. Controlled clinical trials
have not shown improved outcomes in adults with ARDS.
iNO? does not reduce the duration of mechanical ventila-
tion or improve survival in ARDS. The use of iNO? in
ARDS should be restricted to centers performing clinical
trials investigating its use in selected subgroups of patients
with ARDS.
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